$ETSY

Silverman Josh sold $7.5M of ETSY

Silverman Josh sold 102,479 shares of ETSY INC (ETSY) at an average of $73.27 ($72.50–$74.00, $7.51M total) across 2 trades over 2026-06-15 to 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Silverman Josh
Published Jun 17, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
medium confidence
Mentioned
$ETSY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

The newest information is the disclosed open-market sale by a director (Josh Silverman) totaling ~$7.51M across two trades, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying fundamentals.

03

What to watch

The filing doesn’t indicate whether other insiders or large holders changed positions, nor does it provide any new operational or financial information.

Relevance 5/10Novelty 6/10Timing: Filed June 17; trades occurred June 15–16

Background

The article is an SEC Form 4 insider transaction disclosure for Etsy, Inc. (ETSY).

Company-level read

Ticker impact

$ETSYNeutralMedium confidence
Context

SEC Form 4 shows director Josh Silverman sold 102,479 ETSY shares in open-market trades for about $7.51M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses transaction size and timing, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens inference about near-term company outlook.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale often reflects scheduled liquidity needs rather than bearish expectations, so the market may ignore it.

Key entities

  • ETSY

    Issuer of the SEC Form 4 insider transaction; director sold 102,479 shares in June 15–16 trades.

  • Josh Silverman

    Director who executed the open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.